Arginine-Vasopressin in severe septic vs. non-septic shock in extremely low birth weight infants with acute renal failure

Meyer, Sybille G.E.; Baghai, Ali; Löffler, G.; Wurm, D.; Gottschling, Sven; Gortner, Ludwig

doi:10.1055/s-2006-943137

Cited by 14 publications

(45 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Measuring blood pressure (BP) is considered an important part of cardiovascular monitoring in the neonate and frequently forms the basis for cardiovascular treatment protocols. [1][2][3][4][5][6] Techniques for measuring BP in preterm neonates are either non-invasive (NIBP) measurements with a cuff or invasive (IBP) measurements through an indwelling arterial catheter. [7][8][9] Several studies have compared automated oscillometric methods with intra-arterial BP monitoring in neonates, and they have demonstrated a good correlation between mean BP measurements.…”

Section: Introductionmentioning

confidence: 99%

Agreement of invasive versus non‐invasive blood pressure in preterm neonates is not dependent on birth weight or gestational age

Meyer

Sander

Gräber

et al. 2010

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Agreement of invasive versus non‐invasive blood pressure in preterm neonates is not dependent on birth weight or gestational age

Meyer

Sander

Gräber

et al. 2010

J Paediatrics Child Health

View full text Add to dashboard Cite

show abstract

“…Hypotensive, catecholamineresistant shock is increasingly recognized as a cause of death in the post-resuscitation period. Arginine-vasopressin (AVP) and terlipressin (TP) are capable of improving blood pressure but not without adverse effects such as limb gangrene [2][3][4][5][6]. The action of AVP is mediated via two receptors, vascular V1, leading to arterial vasoconstriction, and renal tubular V2.…”

Section: Sepsis Treatmentmentioning

confidence: 99%

“…Landry and colleagues [2] reported the beneficial effect of AVP in critically ill adults with septic shock resistant to inotropic therapy. AVP and TP have now been studied in both adults and children as rescue therapy for catecholamineresistant shock [2][3][4][5]7]. Meyer and colleagues [5] reported the use of AVP infusion in six extremely low birth weight (ELBW) infants with catecholamine-resistant shock.…”

Section: Sepsis Treatmentmentioning

confidence: 99%

“…AVP and TP have now been studied in both adults and children as rescue therapy for catecholamineresistant shock [2][3][4][5]7]. Meyer and colleagues [5] reported the use of AVP infusion in six extremely low birth weight (ELBW) infants with catecholamine-resistant shock. The patients were divided into two groups: (a) septic shock (two bacterial and one fungal) and (b) non-sepsis-induced shock.…”

Section: Sepsis Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Year in review 2006: Critical Care – paediatrics

Amoretti

Tasker

2007

Crit Care

View full text Add to dashboard Cite

In 2006, paediatric intensive care-related subjects were discussed in a number of papers published in various journals, including Critical Care. Because they focused on the cardiovascular system and its support, we summarize them here. In particular, these papers highlighted the management of refractory septic shock, extracorporeal support, outcome markers in sepsis, and outcome after cardiac arrest. IntroductionIn 2006, the paediatric intensive care (PIC) cardiovascularrelated subjects that were discussed in Critical Care included sepsis, viral infection, extracorporeal circulatory support, and outcome after cardiopulmonary arrest. Sepsis TreatmentIn children, death and morbidity from sepsis and septic shock are particular problems [1]. Hypotensive, catecholamineresistant shock is increasingly recognized as a cause of death in the post-resuscitation period. Arginine-vasopressin (AVP) and terlipressin (TP) are capable of improving blood pressure but not without adverse effects such as limb gangrene [2][3][4][5][6]. The action of AVP is mediated via two receptors, vascular V1, leading to arterial vasoconstriction, and renal tubular V2.Landry and colleagues [2] reported the beneficial effect of AVP in critically ill adults with septic shock resistant to inotropic therapy. AVP and TP have now been studied in both adults and children as rescue therapy for catecholamineresistant shock [2][3][4][5]7]. Meyer and colleagues [5] reported the use of AVP infusion in six extremely low birth weight (ELBW) infants with catecholamine-resistant shock. The patients were divided into two groups: (a) septic shock (two bacterial and one fungal) and (b) non-sepsis-induced shock. All patients presented with acute renal injury and were receiving norepinephrine/epinephrine (NE/E) and hydrocortisone. The three patients with septic shock showed improvement in blood pressure, urine output, and serum lactate level after starting AVP. In addition, the NE/E infusion doses could be reduced. There was one death in these three patients, and the AVP infusion was required for 70 ± 21 hours. In patients with non-sepsis-related shock, blood pressure and urine output improved during the first few hours of infusion, but this effect was not sustained. All three patients in this group died. The authors suggested that AVP may be of use in septic shock in the ELBW population. However, a question remains as to the mechanism of action of AVP and whether there is relative AVP deficiency in this population [4,8].TP, a synthetic analog of AVP with a longer half-life, was tested in a prospective, multicentre study reported by Rodríguez-Núñez and colleagues [4]. Critically ill children presenting with catecholamine-resistant septic shock in any of nine PIC units in Spain were enrolled for rescue therapy (TP 0.02 mg/kg, four times hourly). Sixteen children ages 1 month to 13 years (eight patients with meningococcal disease [MD], two patients with Staphylococcus aureus sepsis, and six cases with sepsis of unknown origin) were enrolled after being treated ...

show abstract

“…13 Vasopressin has been reported to attenuate elevated pulmonary vascular resistance in neonates after surgical correction of anomalous pulmonary venous return. 14 These findings have led to a gradual intension creep of the clinical indications for use of vasopressin, from pediatric distributive shock, 15 to refractory hypotension in extremely low birth weight infants, 16 to refractory hypoxic pulmonary hypertension; this last indication is supported mainly by case report evidence. [17][18][19] An international survey of practice patterns in management of refractory PPHN revealed higher use of vasopressin in Canada, compared to other countries.…”

mentioning

confidence: 99%

Effect of vasopressin on a porcine model of persistent pulmonary hypertension of the newborn

Amer

Elsayed

Graham

et al. 2019

Pediatric Pulmonology

View full text Add to dashboard Cite

Background Persistent pulmonary hypertension of the newborn (PPHN) is due to a failure of pulmonary vascular relaxation. Vasopressin, a systemic vasoconstrictor acting on smooth muscle AVPR1a receptors, is used in treatment of PPHN. We sought to determine acute effects of vasopressin infusion on pulmonary hemodynamics in a large animal model of hypoxic PPHN. Methods PPHN was induced in 6 newborn piglets by 72 h normobaric hypoxia (FiO2 = 0.10); controls were 7 age‐matched 3‐day‐old piglets. Animals were anesthetized and ventilated with central venous and arterial lines, and after stabilization, randomized using a crossover design to normoxic or hypoxic ventilation, then 30 min infusion of 0.0012 U/kg/min vasopressin, followed by 45 min vasopressin washout period. Echocardiographic parameters and oxygen consumption were measured before and after vasopressin. Relaxation to vasopressin was tested in isolated PPHN and control pulmonary arteries by isometric myography. Expression of AVPR1a receptor mRNA was quantified in arterial and myocardial tissues. Results Vasopressin did not alleviate hypoxia‐responsiveness of PPHN pulmonary circuit. There were no significant differences in pulmonary hypertension, cardiac function indices, or oxygenation indices after vasopressin infusion. Vasopressin did not dilate control or PPHN pulmonary arteries, and AVPR1 was minimally expressed. Conclusions Vasopressin does not have a direct pulmonary vasodilator effect in PPHN, within the timeframe studied.

show abstract

Arginine-Vasopressin in severe septic vs. non-septic shock in extremely low birth weight infants with acute renal failure

Cited by 14 publications

References 0 publications

Agreement of invasive versus non‐invasive blood pressure in preterm neonates is not dependent on birth weight or gestational age

Agreement of invasive versus non‐invasive blood pressure in preterm neonates is not dependent on birth weight or gestational age

Year in review 2006: Critical Care – paediatrics

Effect of vasopressin on a porcine model of persistent pulmonary hypertension of the newborn

Contact Info

Product

Resources

About